Patients aged 18-70 years old, male or female, signing the informed consent form; patients with recurrent malignant glioma grade III and above; patients with unilateral, single-focal, supratentorial tumors (non-primary sites in recurrence cannot be enrolled; patients whose lesions started as multiple, and recurred again after surgical resection (single-focal) cannot be enrolled; patients with recurrent, single-focal glioblastomas but with peripheral molluscan metastases also Patients with recurrent single-focal glioblastoma with peripheral soft meningeal metastases are not eligible for enrollment; patients with first recurrence of malignant glioma (second surgery); patients with at least one radiotherapy treatment prior to enrollment, and the time between the last radiotherapy treatment and the start of the trial is more than 4 weeks (or more than 6 weeks for patients with nitrosoureas); patients with a Kasperger’s Quality of Life Score (KPS) of ≥ 60; and patients with no hematological disorders, i.e., preenrollment Hb ≥ 90 g/L, WBC ≥ 3.0109/ L, ANC ≥ 1.025/ L. L, ANC ≥ 1.5109/L, PLT ≥ 100×109/L; no obvious abnormality on electrocardiogram; liver and kidney functions are not seriously impaired: liver function tests: TBIL ≤ 1.5 times the upper limit of the normal value, AST, ALT ≤ 2.5 times the upper limit of the normal value; renal function tests: CR, BUN ≤ 1.5 times the upper limit of the normal value; the patient must be non-pregnant and non-breastfeeding if she is a woman of childbearing age, If the patient is a woman of childbearing age, she must not be pregnant, breastfeeding, or lactating, and agree not to become pregnant during the trial period. The patient’s Kahn’s Quality of Life Score (KPS) is ≥ 60;